Overcoming resistance to anti-EGFR therapy — where do we stand?
Crossref DOI link: https://doi.org/10.1038/nrgastro.2016.52
Published Online: 2016-03-23
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schirripa, Marta
Lenz, Heinz-Josef
Text and Data Mining valid from 2016-03-23
Article History
First Online: 23 March 2016
Competing interests
: H.-J.L. has received honoraria for speaking and for clinical trial support from Merck Serono and Roche. M.S. declares no competing interests.